XSWX
EVE
Market cap19mUSD
Oct 09, Last price
2.19CHF
1D
-1.35%
1Q
-0.90%
Jan 2017
-98.57%
IPO
-99.92%
Name
Evolva Holding SA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Evolva Holding SA is a Swiss-headquartered firm, established in 2004, that operates internationally, including in the United States. The company focuses on identifying, scientifically exploring, advancing, and bringing to market natural, bio-based ingredients. These innovative compounds are utilized across a range of sectors, such as the creation of flavors and fragrances, health and wellness products, and protective health solutions. Evolva's diverse product portfolio includes: Veri-te Resveratrol: A plant-derived polyphenol naturally present in grapes, peanuts, cranberries, and other berries. L-Arabinose: A flavoring agent essential for the Maillard reaction. Valencene: An aromatic component found in citrus fruits and derived from citrus. Nootkatone: A grapefruit aroma ingredient produced through the biochemical oxidation of valencene. Vanillin: The principal aromatic constituent extracted from vanilla beans.
Key people
Paul Verbraeken
Vice President Investors Relations
Stuart Strathdee
Non-Executive Director · since 2011
Thomas Videbaek
Non-Executive Director · since 2012
Legal address
Angensteinerstrasse 6
Reinach BL, BL 4153
CH
Reinach BL, BL 4153
CH
Headquarters
Duggingerstrasse 23
Reinach BL, BL 4153
CH
Reinach BL, BL 4153
CH
Previous name
Evolva Holding SA
Previous name
Evolva Holding SA in Liquidation
Other language
EvoNext Holdings AG
Other language
EvoNext Holdings Ltd
Valuation
Title CHF in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||